IPSC (Century Therapeutics) NonCurrent Deferred Liabilities: $4.3 Mil (As of Mar. 2026)


IPSC Century Therapeutics Inc IPSC
46 GF Score
Price $2.32
GF Value $38.91
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Century Therapeutics NonCurrent Deferred Liabilities?

Century Therapeutics IPSC -3.75% 46 NonCurrent Deferred Liabilities is $4.3 Mil as of Mar. 2026. GuruFocus rates IPSC with a GF Score™ of 46/100 and a GF Value™ of $38.91 (Possible Value Trap). The stock has 3 warning signs investors should review.

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Century Therapeutics's non-current deferred liabilities for the quarter that ended in Mar. 2026 was $4.3 Mil.

Century Therapeutics NonCurrent Deferred Liabilities Related Terms

Century Therapeutics NonCurrent Deferred Liabilities Historical Data

* Premium members only.

The historical data trend for Century Therapeutics's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Century Therapeutics NonCurrent Deferred Liabilities Chart

Century Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
NonCurrent Deferred Liabilities
Get a 7-Day Free Trial 0.00 110.83 111.38 4.37 4.30

Century Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
NonCurrent Deferred Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.37 4.37 4.37 4.30 4.30
IPSC
46GF Score
Century Therapeutics Inc IPSC
NonCurrent Deferred Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a NonCurrent Deferred Liabilities of $4.3 Mil mean?
Century Therapeutics (IPSC) has a NonCurrent Deferred Liabilities of $4.3 Mil as of Mar. 2026. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Century Therapeutics and its competitors.
Is Century Therapeutics' NonCurrent Deferred Liabilities too high?
Century Therapeutics' current NonCurrent Deferred Liabilities is $4.3 Mil. Overall, Century Therapeutics has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Century Therapeutics' NonCurrent Deferred Liabilities compare to PBYI and BNTC?
Century Therapeutics' NonCurrent Deferred Liabilities of $4.3 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Liabilities for a Biotechnology company?
A good NonCurrent Deferred Liabilities depends on the Biotechnology industry context. However, NonCurrent Deferred Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Liabilities mean?
A high NonCurrent Deferred Liabilities can signal that a stock is expensive relative to its fundamentals. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Century Therapeutics and its competitors. Century Therapeutics's current NonCurrent Deferred Liabilities is $4.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Century Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Century Therapeutics (IPSC) is currently considered Possible Value Trap. The stock's GF Value™ is $38.91, compared to a current price of $2.32 — trading 94.1% below its estimated fair value. The current NonCurrent Deferred Liabilities is $4.3 Mil. Century Therapeutics' overall GF Score™ is 46/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Liabilities calculated?
NonCurrent Deferred Liabilities is calculated from a company's financial statements. For Century Therapeutics (IPSC), the current NonCurrent Deferred Liabilities is $4.3 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Century Therapeutics (IPSC) Overvalued in 2026?

Based on GuruFocus' analysis, Century Therapeutics stock appears to be undervalued. The current stock price of $2.32 is trading 94.1% below its estimated GF Value™ of $38.91. GuruFocus considers Century Therapeutics to be Possible Value Trap.

Key valuation signals for IPSC:

  • NonCurrent Deferred Liabilities: $4.3 Mil
  • GF Value™: $38.91 vs. price of $2.32 (94.1% below fair value)
  • GF Score™: 46/100 with 3 warning signs

No single metric tells the full story. See the IPSC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Century Therapeutics Business Description

Address 25 N 38th Street, 11th Floor, Philadelphia, PA, USA, 19104
Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.
46GF Score

Get the complete analysis for IPSC

NonCurrent Deferred Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.32
Price
$38.91
GF Value